130 related articles for article (PubMed ID: 22942827)
1. Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis.
Raborn ML; Pelletier EM; Smith DB; Reyes CM
J Oncol Pract; 2012 May; 8(3 Suppl):9s-15s. PubMed ID: 22942827
[TBL] [Abstract][Full Text] [Related]
2. Patient out-of-pocket payments for oral oncolytics: results from a 2009 US claims data analysis.
Raborn ML; Pelletier EM; Smith DB; Reyes CM
Am J Manag Care; 2012 May; 18(5 Spec No. 2):SP57-64. PubMed ID: 22693982
[TBL] [Abstract][Full Text] [Related]
3. Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit.
Rotenstein LS; Dusetzina SB; Keating NL
J Manag Care Spec Pharm; 2018 Jun; 24(6):494-502. PubMed ID: 29799324
[TBL] [Abstract][Full Text] [Related]
4. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
Bibeau WS; Fu H; Taylor AD; Kwan AY
J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
[TBL] [Abstract][Full Text] [Related]
5. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
6. Patient out-of-pocket spending in cranial neurosurgery: single-institution analysis of 6569 consecutive cases and literature review.
Yoon S; Mooney MA; Bohl MA; Sheehy JP; Nakaji P; Little AS; Lawton MT
Neurosurg Focus; 2018 May; 44(5):E6. PubMed ID: 29712524
[TBL] [Abstract][Full Text] [Related]
7. Out-of-pocket payments in the context of a free maternal health care policy in Burkina Faso: a national cross-sectional survey.
Meda IB; Baguiya A; Ridde V; Ouédraogo HG; Dumont A; Kouanda S
Health Econ Rev; 2019 Mar; 9(1):11. PubMed ID: 30919219
[TBL] [Abstract][Full Text] [Related]
8. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.
Hopson S; Saverno K; Liu LZ; AL-Sabbagh A; Orazem J; Costantino ME; Pasquale MK
J Manag Care Spec Pharm; 2016 Feb; 22(2):122-30. PubMed ID: 27015251
[TBL] [Abstract][Full Text] [Related]
9. Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Kaye DR; Lee HJ; Gordee A; George DJ; Ubel PA; Scales CD; Bundorf MK
JCO Oncol Pract; 2023 Apr; 19(4):e600-e617. PubMed ID: 36689695
[TBL] [Abstract][Full Text] [Related]
10. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
[TBL] [Abstract][Full Text] [Related]
11. Cost Transparency in Neurosurgery: A Single-Institution Analysis of Patient Out-of-Pocket Spending in 13 673 Consecutive Neurosurgery Cases.
Mooney MA; Yoon S; Cole T; Sheehy JP; Bohl MA; Barranco FD; Nakaji P; Little AS; Lawton MT
Neurosurgery; 2019 Jun; 84(6):1280-1289. PubMed ID: 29767766
[TBL] [Abstract][Full Text] [Related]
12. Estimation of Patient Out-of-Pocket Cost for Radiation Therapy by Insurance Type and Treatment Modality.
Chen LW; Cao Y; D'Rummo K; Shen X
Pract Radiat Oncol; 2022; 12(6):e481-e485. PubMed ID: 35447387
[TBL] [Abstract][Full Text] [Related]
13. The association of financial difficulties and out-of-pocket payments with health-related quality of life among breast, prostate and colorectal cancer patients.
Koskinen JP; Färkkilä N; Sintonen H; Saarto T; Taari K; Roine RP
Acta Oncol; 2019 Jul; 58(7):1062-1068. PubMed ID: 30943813
[No Abstract] [Full Text] [Related]
14. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?
Curkendall S; Patel V; Gleeson M; Campbell RS; Zagari M; Dubois R
Arthritis Rheum; 2008 Oct; 59(10):1519-26. PubMed ID: 18821651
[TBL] [Abstract][Full Text] [Related]
15. The Increasing Financial Burden of Outpatient Elective Surgery for the Privately Insured.
Billig JI; Lan WC; Chung KC; Kuo CF; Sears ED
Ann Surg; 2020 Sep; 272(3):530-536. PubMed ID: 32740255
[TBL] [Abstract][Full Text] [Related]
16. Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims.
Vyas A; Descoteaux A; Kogut S; Parikh MA; Campbell PJ; Green A; Westrich K
J Manag Care Spec Pharm; 2022 Aug; 28(8):831-844. PubMed ID: 35876294
[No Abstract] [Full Text] [Related]
17. Forgone care and financial burden due to out-of-pocket payments within the German health care system.
Bremer P
Health Econ Rev; 2014 Dec; 4(1):36. PubMed ID: 26208936
[TBL] [Abstract][Full Text] [Related]
18. Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018.
Peet ED; Powell D; Pacula RL
JAMA Health Forum; 2022 Aug; 3(8):e222663. PubMed ID: 36200636
[TBL] [Abstract][Full Text] [Related]
19. Out-of-Pocket Cost Modeling of Adjuvant Radiation Therapy Duration in Standard-of-Care Early Stage Breast Cancer Treatment Across Medicaid and Medicare Plans.
Wu VS; Khlopin M; Jagsi R; McClelland S
Pract Radiat Oncol; 2024; 14(1):24-27. PubMed ID: 37748680
[TBL] [Abstract][Full Text] [Related]
20. Out-of-Pocket and Total Costs for Common Hand Procedures From 2008 to 2016: A Nationwide Claims Database Analysis.
Michaud JB; Zhuang T; Shapiro LM; Cohen SA; Kamal RN
J Hand Surg Am; 2022 Nov; 47(11):1057-1067. PubMed ID: 35985865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
